Abstract
Human umbilical vein endothelial cells (HUVECs) have played a major role as a model system for the study of the regulation of endothelial cell function and the role of the endothelium in the response of the blood vessel wall to stretch, shear forces, and the development of atherosclerotic plaques and angiogenesis. Here, we use HUVECs and human microvascular endothelial cells to study the role of the HMG-CoA reductase inhibitor, simvastatin, and the small GTP-binding protein Rho in the regulation of angiogenesis. Simvastatin inhibited angiogenesis in response to FGF-2 in the corneal pocket assay of the mouse and in vascular endothelial growth factor (VEGF)-stimulated angiogenesis in the chick chorioallontoic membrane. Furthermore, simvastatin inhibited VEGF-stimulated tube formation by human dermal microvascular endothelial cells and the formation of honeycomb-like structures by HUVECs. The effect was dose-dependent and was not secondary to apoptosis. Geranylgeranyl-pyrophosphate (GGPP), a product of the cholesterol metabolic pathway that serves as a substrate for the posttranslational lipidation of RhoA, was required for membrane localization, but not farnesylpyrophosphate (FPP), the substrate for the lipidation of Ras. Furthermore, GGTI, a specific inhibitor of GGPP, mimicked the effect of simvastatin of tube formation and the formation of honeycombs whereas FTI, a specific inhibitor of the farnesylation of Ras, had no effect. Adenoviral expression of a DN-RhoA mutant mimicked the effect of simvastatin on tube formation and the formation of honeycombs, whereas a dominant activating mutant of RhoA reversed the effect of simvastatin on tube formation. Finally, simvastatin interfered with the membrane localization of RhoA with a dose-dependence similar to that for the inhibition of tube formation. Simvastatin also inhibited the VEGF-stimulated phosphorylation of the VEGF receptor KDR, and the tyrosine kinase FAK, which plays a role in cell migration. These data demonstrate that simvastatin interfered with angiogenesis via the inhibition of RhoA. Data supporting a role for angiogenesis in the development and growth of atherosclerotic plaques suggest that this antiangiogenic effect of Statins might prevent the progression of atherosclerosis via the inhibition of plaque angiogenesis.
Similar content being viewed by others
References
Yamada T, Fan J, Shimokama T, Tokunaga O, Watanabe T. Am J Pathol 1992;241(6):1435–1444.
Bevilacqua MP, Gimbrone MA, Jr. 1987;13(4):425–433.
Libby P. J Intern Med 2000;247(3):349–358.
Davies PF. J Vasc Res 1997;34(3):208–211.
Gimbrone MA, Jr. Prog Hemost Thromb 1976;3:1–28.
Goldberger A, Middleton KA, Oliver JA, et al. J Biol Chem 1994; 269(25):17,183–17,191.
Namiki A, Brogi E, Kearney M, et al. J Biol Chem 1995;270 (52):31,189–31,195.
Nozawa F, Hirota M, Okabe A, et al. Pancreas 2000;21(4):392–398.
Muscella A, Marsigliante S, Carluccio MA, Vinson GP, Storelli C, et al. J Endocrinol 1997;155(3):587–593.
Burns MP, DePaola N. Am J Physiol Heart Circ Physiol 2005; 288(1):H194-H204.
Kokura S, Wolf RE, Yoshikawa T, Granger DN, Aw TY. Circ Res 1999;84(5):516–524.
Zhang W, DeMattia JA, Song H, Couldwell WT. J Neurosurg 2003;98(4):846–853.
Bevilacqua MP, Stengelin S, Gimbrone MA, Jr, Seed B, et al. Science 1989;243(4895):1160–1165.
Parmar KM, Larman HB, Dai G, et al. J Clin Invest 2006; 116(1):49–58.
Parmar KM, Nambudiri V, Dai G, Larman HB, et al. J Biol Chem. 2005;280(29):26,714–26,719.
Dai G, Kaazempur-Mofrad MR, Natarajan S, et al. Proc Natl Acad Sci USA 2004;101(41):14,871–14,876.
Kumar S, Li C. Trends Immunol 2001;22(3):129.
Yoon YS, Johnson IA, Park JS, Diaz L, Losordo DW. Mol Cell Biochem 2004;264(1–2):63–74.
Nagata D, Mogi M, Walsh K. J Biol Chem 2003;278(33):31,000–31,006.
Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. Circ Res 2002;91(2):143–150.
Weis M, Heeschen C, Glassford AJ, Cooke JP. Circulation 2002;105(6):739–745.
Goldstein JL, Brown MS. Nature 1990;343(6257):425–430.
Grundy SM. Circulation 1998;97(15):1436–1439.
Massy ZA, Keane WF, Kasiske BL. Lancet 1996;347(8994):102–103.
Sacks FM, Moye LA, Davis BR, et al. Circulation 1998;97(15):1446–1452.
Laufs U, La Fata V, Plutzky J, Liao JK. Circulation 1998;97(12):1129–1135.
Lerner EC, Qian Y, Blaskovich MA, et al. J Biol Chem 1995;270(45):26,802–26,806.
Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Oncogene 1996;13(9):1991–1999.
Ernst JD. Cell Microbiol 2000;2(5):379–386.
Gossen M, Bujard H. Proc Natl Acad Sci USA 1992;89(12):5547–5551.
Gingras D, Lamy S, Beliveau R. Biochem J 2000;348(Part 2):273–280.
Clark EA, King WG, Brugge JS, Symons M, Hynes RO. J Cell Biol 1998;142(2):573–586.
Robert P, Tsui P, Laville MP, et al. J Mol Cell Cardiol 2001; 33(9):1589–1606.
Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Circ Res 2002;90(6):737–744.
Feleszko W, Balkowiec EZ, Sieberth E, et al. Int J Cancer 1999;81(4):560–567.
Vincent L, Chen W, Hong L, et al. FEBS Lett 2001;495(3):159–166.
Williams JK, Sukhova GK, Herrington DM, Libby P. J Am Coll Cardiol 1998;31(3):684–691.
Wilson SH, Herrmann J, Lerman LO, et al. Circulation 2002;105(4):415–418.
Gordon B, Chang S, Kavanagh M, et al. Am J Ophthalmol 1991;112(4):385–391.
Folkman J. Nat Med 1995;1(1):27–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, HJ., Zhang, Y., Georgescu, S.P. et al. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2, 93–101 (2006). https://doi.org/10.1007/s12015-006-0015-x
Issue Date:
DOI: https://doi.org/10.1007/s12015-006-0015-x